Back to Results

Sino Biopharmaceutical Ltd ADR (SBHMY)

Sino Biopharmaceutical Limited ADR is a depositary receipt representing common stock of Sino Biopharmaceutical Limited, which is listed on OTC Markets under OTC-SBHM.Y. The underlying issuer is an investment holding company and pharmaceutical group based in Wan Chai, Hong Kong, with operations focused on research and development in the People’s Republic of China. Its business is organized across modernised Chinese medicines and chemical medicines, investment, and other activities. The company markets a range of prescription medicines in areas such as oncology, liver disease, respiratory care, and surgery/analgesia, and it also advances additional drug candidates in these therapeutic fields. Beyond its core pharmaceutical operations, Sino Biopharmaceutical is involved in long-term investments and healthcare and hospital-related businesses.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-SBHM.Y
$17.47
37.8% Upside
Undervalued
—
—
—
Great
June 25, 2026
August 4, 2026
0.21
1.6%
August 13, 2026
33.9x
2.6x
2.5x
11.603 B
8.633 B
15.0%
48.9%
7.1
64.1%
343.7%
Valuation • Fair Value

Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$17.47

Estimated upside of 37.8% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$21.82

Discounted cash flow valuation reference.

Ben Graham Formula Value

$4.16

Classic Ben Graham valuation formula reference.

DDM Fair Value

$22.42

Dividend discount model valuation reference.

EPV Fair Value

$21.06

Earnings power value estimate.

Comps Fair Value

$13.16

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

4.552 B

Current operating scale indicator.

Revenue Forecast

5.328 B

Forward revenue estimate.

EBITDA

1.037 B

Current operating profitability reference.

EBITDA Forecast

1.381 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.84

No elevated caution signal from this screen.

Altman Z-Score

7.1

Relatively strong balance-sheet zone.

FCF / Net Income

343.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 13, 2026

Days to Earnings

23

Dividend Payment Date

August 4, 2026

Ex-Dividend Date

June 25, 2026

Dividend Yield

1.6%

Income yield reference.

Upcoming Dividend

0.21

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

64.1%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) Stock Forecast & Technical Outlook

Review Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) Stock FAQ

Quick answers about Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$17.47
Estimated upside 37.8%
Valuation Rating
Undervalued
Estimated upside of 37.8%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Great
Current financial-health read

The current fair value estimate for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is $17.47. This implies an estimated upside of 37.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 37.8% versus the current market price.

An analyst price target for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is not currently available in the latest data file.

The current financial health read for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is August 13, 2026.

Based on the current data, dividend yield is 1.6%, upcoming dividend amount is 0.21, ex-dividend date is June 25, 2026, payment date is August 4, 2026.

The current P/E ratio listed for Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is 33.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Sino Biopharmaceutical Ltd ADR is 11.603 B.

The current enterprise value listed for Sino Biopharmaceutical Ltd ADR is 8.633 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Sino Biopharmaceutical Ltd ADR is OTC-SBHM.Y, and the stock is listed on OTC Markets.

Sino Biopharmaceutical Ltd ADR (OTC-SBHM.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Sino Biopharmaceutical Ltd ADR is 15.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Sino Biopharmaceutical Ltd ADR is 48.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)
Haw Par Corporation Ltd ADR (HAWPY) Haw Par Corporation Ltd ADR (HAWPY)